HAP Trading’s Heron Therapeutics HRTX Stock Holding History

HAP Trading’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-21,600	Closed	-$107K	–	1713
2020 Q2	$107K	Sell	21,600 -89,700	-81%	-$1.47M	0.01%	836
2020 Q1	$260K	Buy	+111,300	New	+$2.09M	0.02%	480
2019 Q3	–	Sell	-179,600	Closed	-$98K	–	1283
2019 Q2	$98K	Buy	+179,600	New	+$3.59M	0.01%	610
2015 Q3	–	Sell	-25,000	Closed	-$69K	–	1105
2015 Q2	$69K	Buy	+25,000	New	+$470K	﹤0.01%	613

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

HAP Trading's HRTX Position: Q2 2020 in Review

HAP Trading sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 39,115 shares — an estimated $643K sold.

HAP Trading first reported a position in HRTX in Q1 2015 and held it in 9 quarters. The position peaked at $3.22M in Q4 2015. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

HAP Trading reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
HAP Trading sold 39,115 Heron Therapeutics shares in Q2 2020, an estimated $643K.
HAP Trading first reported a position in Heron Therapeutics in Q1 2015 and held it in 9 quarters.
HAP Trading's Heron Therapeutics position peaked at $3.22M in Q4 2015.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on HAP Trading's 13F filing for Q2 2020, filed 10 Aug 2020.